The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.

##STR00001##

A compound represented by formula (I) or a salt thereof, as well as a formulation for controlling harmful organisms, an insecticidal formulation, an acaricidal formulation, a nematicidal formulation, or a formulation for controlling or exterminating endoparasites, containing at least one compound selected from the group consisting of the compounds described above and salts thereof, as an active ingredient.

##STR00001##

In formula (I), Ar.sup.1 is a benzene ring or a 5- to 6-membered heteroaryl ring, R.sup.1 is a C1 to C6 alkyl group, a halogeno group, or the like, n represents the number of R.sup.1 and is 0, 1, 2, or 3, and in the case of n being 2 or more, two or more R.sup.1 may be the same as or different from one another, R.sup.2 is a C1 to C6 alkyl group, a C1 to C6 haloalkyl group, or the like, R.sup.3 is a hydrogen atom, a C1 to C6 alkyl group, a C1 to C6 alkylcarbonyl group, or the like, and AR.sup.2 represents a substituted or unsubstituted heteroaryl group.

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof. ##STR00001##

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof. ##STR00001##

Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.

The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.

The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

##STR00001##